Anti-LPS Antibody Treatment for Pediatric NAFLD

Summary

The main objective of this pilot study is to evaluate whether 12 weeks of IMM-124E in children with nonalcoholic fatty liver disease (NAFLD) in combination with standard of care treatment will decrease inflammation in the liver as measured by alanine transaminase (ALT). Specifically, investigators will measure percent change in ALT from Week 0 to Week 12 in treatment compared to placebo.

Timeline

Start

2017-02-01

Primary completion

2019-10-23

Completion

2019-10-23

Drugs

Indications